Αρχική World News Manageable Safety Profile and Antitumour Activity of Zongertinib in Pretreated Patients with... World News Manageable Safety Profile and Antitumour Activity of Zongertinib in Pretreated Patients with HER2-altered Tumours, Including NSCLC Από Ogkologos - 17 Μαρτίου, 2025 594 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the Beamion LUNG-1 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Nurse Diagnosed with Stage IV Cancer After Thinking Her Pain Was... 23 Μαρτίου, 2021 How I Took Charge of My Cancer Care and Found a... 30 Αυγούστου, 2022 Cómo comenzar a hacer ejercicio en el hogar durante el tratamiento... 18 Ιανουαρίου, 2023 Mylan Recalls Injectable Cancer Drug After Particulates Discovered 20 Μαρτίου, 2019 Φόρτωση περισσοτέρων HOT NEWS Dog Showers His Mom with Snuggles and Makes Her Laugh During... When You Have Cancer and You’re a Parent: “Your Stories” Podcast Quarantined Cruise Ship Passenger Concerned She Won’t Make It Home for... Opinion: ‘Why we need earlier diagnosis of cancer more than ever...